See more : Mitsui O.S.K. Lines, Ltd. (MSLOY) Income Statement Analysis – Financial Results
Complete financial analysis of ARTERRA BIOSCIENCE (ARBS.MI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ARTERRA BIOSCIENCE, a leading company in the Biotechnology industry within the Healthcare sector.
- Prospect Capital Corporation (0R25.L) Income Statement Analysis – Financial Results
- Hainan Huluwa Pharmaceutical Group Co., Ltd. (605199.SS) Income Statement Analysis – Financial Results
- China Power Equipment, Inc. (CPQQ) Income Statement Analysis – Financial Results
- Spotlight Homes, Inc. (SPHM) Income Statement Analysis – Financial Results
- Net One Systems Co., Ltd. (NONEF) Income Statement Analysis – Financial Results
ARTERRA BIOSCIENCE (ARBS.MI)
About ARTERRA BIOSCIENCE
Arterra Bioscience S.p.A., a research-based biotech company, engages in the research and development of various ingredients and natural solutions. It develops technological platforms, extraction processes, and raw materials for use in the cosmetics, agriculture, and nutraceutics sectors. Arterra Bioscience S.p.A. was founded in 2003 and is based in Naples, Italy.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 3.34M | 3.56M | 3.83M | 2.82M | 2.71M | 2.43M | 2.05M |
| Cost of Revenue | 1.57M | 3.07M | 3.15M | 2.79M | 2.38M | 1.72M | 1.50M |
| Gross Profit | 1.77M | 492.76K | 673.14K | 30.83K | 324.93K | 709.32K | 554.08K |
| Gross Profit Ratio | 53.01% | 13.83% | 17.60% | 1.09% | 11.99% | 29.23% | 26.98% |
| Research & Development | 1.83M | 1.64M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | -57.79K | 107.16K | 172.04K | 180.78K | 183.85K | 199.16K | 166.00K |
| Other Expenses | 0.00 | -20.58K | -17.69K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.77M | 127.74K | 189.73K | 180.78K | 183.85K | 199.16K | 166.00K |
| Cost & Expenses | 4.87M | 3.20M | 3.34M | 2.97M | 2.57M | 1.92M | 1.67M |
| Interest Income | 93.04K | 201.06K | 2.64K | 12.04K | 12.45K | 5.70K | 20.00 |
| Interest Expense | 10.03K | 7.51K | 8.16K | 15.43K | 11.88K | 5.70K | 7.28K |
| Depreciation & Amortization | 532.28K | 531.87K | 487.26K | 400.42K | 296.30K | 73.40K | 143.07K |
| EBITDA | 1.84M | 2.13M | 1.77M | 1.60M | 1.24M | 607.96K | 539.31K |
| EBITDA Ratio | 55.29% | 25.17% | 25.37% | 8.88% | 16.14% | 24.04% | 25.86% |
| Operating Income | -1.53M | 365.02K | 483.41K | -149.95K | 141.08K | 510.16K | 388.08K |
| Operating Income Ratio | -45.97% | 10.24% | 12.64% | -5.31% | 5.21% | 21.02% | 18.90% |
| Total Other Income/Expenses | 2.84M | 828.03K | -648.06K | -432.16K | -345.64K | 399.70K | -6.48K |
| Income Before Tax | 1.30M | 1.80M | 1.27M | 1.19M | 928.03K | 1.06M | 1.01M |
| Income Before Tax Ratio | 39.03% | 50.44% | 33.23% | 42.08% | 34.25% | 43.71% | 49.02% |
| Income Tax Expense | 226.03K | 383.38K | 163.38K | 90.70K | 83.23K | 29.27K | 272.12K |
| Net Income | 1.08M | 1.41M | 1.11M | 1.11M | 857.24K | 1.04M | 745.26K |
| Net Income Ratio | 32.26% | 39.68% | 29.03% | 39.29% | 31.64% | 43.02% | 36.29% |
| EPS | 0.16 | 0.21 | 0.17 | 0.17 | 0.13 | 0.16 | 0.11 |
| EPS Diluted | 0.16 | 0.21 | 0.17 | 0.17 | 0.13 | 0.16 | 0.11 |
| Weighted Avg Shares Out | 6.66M | 6.66M | 6.66M | 6.54M | 6.54M | 6.54M | 6.54M |
| Weighted Avg Shares Out (Dil) | 6.66M | 6.66M | 6.66M | 6.54M | 6.54M | 6.54M | 6.54M |
Source: https://incomestatements.info
Category: Stock Reports